<AbstractText><em>Nesfatin</em>-<em>1</em> is a novel peptide with both central and peripheral anorexigenic regulatory properties. Besides its effects on food intake, few studies have suggested a possible role for this peptide in the pathogenesis of diabetes mellitus type 2.</AbstractText><AbstractText>To compare serum levels of <em>nesfatin</em>-<em>1</em> between healthy, normal-weight persons and three groups including healthy underweight, healthy obese and diabetic subjects.</AbstractText><AbstractText>Prospective, case-control study, performed between January 20<em>1</em>5 and January 20<em>1</em>6.</AbstractText><AbstractText>Fasting levels in serum <em>nesfatin</em>-<em>1</em> were measured in 30 healthy, normal-weight individuals (controls), 30 healthy underweight persons, 30 healthy obese persons, and 30 patients with newly diagnosed diabetes type 2 using standard enzyme-linked immunosorbent assay (ELISA) kits.</AbstractText><AbstractText>The mean serum <em>nesfatin</em>-<em>1</em> level was significantly higher in controls (2.6<em>1</em> ng/mL) compared to that in obese (<em>1</em>.<em>1</em>3 ng/mL) and diabetic (0.99 ng/mL) patients; and significantly lower than that in the underweight group (3.50 ng/mL). The obese and diabetic groups were comparable in this regard. No significant association was found between serum <em>nesfatin</em>-<em>1</em> level and age, sex, or body mass index.</AbstractText><AbstractText>Serum <em>nesfatin</em>-<em>1</em> is possibly associated with weight-related abnormalities in otherwise healthy subjects and diabetes type 2. Obesity and diabetes type 2 may share a common pathologic point in this regard.</AbstractText>

<strong class="sub-title"> Purpose: </strong> The aim of this study was to evaluate the immunoreactivity of matrix metalloproteinases-2 (MMP-2), intercellular adhesion molecule-<em>1</em> (ICAM-<em>1</em>), and <em>nesfatin</em>-<em>1</em> in cataract lens epithelial cells (LECs) of patients with diabetes mellitus (DM) and to investigate the relationship of these markers with DM cataract and diabetic retinopathy (DR).

<strong class="sub-title"> Materials and methods: </strong> Ninety patients were included in the study. The patients were divided into three groups (<i>n</i> = 30): Group <em>1</em> (control; patients without DM or DR); Group 2 (patients with DM only), and Group 3 (patients with both DM and DR). Lens capsule samples were collected during intraoperative cataract surgery. Samples were immunohistochemically stained for MMP-2, ICAM-<em>1</em>, and <em>nesfatin</em>-<em>1</em> and their immunoreactivity was evaluated. The number of immunoreactive cells was determined with a microscope at ×400 magnification.

<strong class="sub-title"> Results: </strong> Increased MMP-2 and ICAM-<em>1</em> immunoreactivity was detected in the LECs of patients with DM, and especially in patients with DR (<i>p</i> < 0.00<em>1</em>, <i>p</i> < 0.00<em>1</em>, respectively). Nesfatin-<em>1</em> immunoreactivity was significantly lower in LECs of diabetic patients (<i>p</i> < 0.00<em>1</em>). The mean of MMP-2 immunoreactive cells were 7.47 ± 8.<em>1</em>8, 22.80 ± <em>1</em>5.70, and 34.80 ± 20.85 in Groups <em>1</em>, 2, and 3, respectively. The mean of ICAM-<em>1</em> immunoreactive cells were <em>1</em>7.<em>1</em>0 ± 9.83, 38.50 ± 23.55, and 56.93 ± 20.94 in Groups <em>1</em>, 2, and 3, respectively.

<strong class="sub-title"> Conclusion: </strong> Nesfatin-<em>1</em>, MMP-2, and ICAM-<em>1</em> and could potentially play important roles in the pathogenesis of cataracts in patients with DM.

<strong class="sub-title"> Keywords: </strong> Cataract; ICAM-<em>1</em>; MMP-2; Nesfatin-<em>1</em>; diabetes mellitus; diabetic retinopathy; immunohistochemistry.

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition dur-ing pregnancy. Explanation of the GDM pathogenesis is important due to preventing gestational complications. During pregnancy there are significant changes in maternal metabolism. Many of these changes are influenced by different adi-pokines produced in the placenta and adipose tissue. The exact role of adipokines in the pathogenesis of GDM remains still unknown. Several adipokines have been analysed throughout gestation and their levels have been suggested as biomarkers of maternal-perinatal outcomes. Some of them have been postulated as significant in the pathogenesis of pregnancy complications like GDM. This report aims to review some of the recent topics of adipokine research that may be of particular importance in patho-physiology and diagnosis of gestational diabetes mellitus. Because of manuscript length limitations, after thorough literature review and in view of the recent evidence, we focus on the one of the most well-known adipokine: adiponectin, and not so well-studied: <em>nesfatin</em>-<em>1</em>, chemerin, ghrelin, and CTRP <em>1</em>.

<strong class="sub-title"> Objectives: </strong> This study aims to investigate the relationship between serum level of <em>nesfatin</em>-<em>1</em> and fibromyalgia syndrome (FMS) clinical parameters such as pain severity, disease activity, fatigue, emotional state, and sleep quality.

<strong class="sub-title"> Patients and methods: </strong> Forty-six female patients with FMS (median age 40 years; range, <em>1</em>8 to 53 years) and 46 healthy female controls (median age 36 years; range, <em>1</em>9 to 52 years) were included in the study. Severity of pain, disease activity, fatigue, sleep quality, and emotional status were evaluated by visual analog scale, Fibromyalgia Impact Questionnaire, Multidimensional Assessment of Fatigue (MAF), Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI), respectively. Serum <em>nesfatin</em>-<em>1</em> concentrations (pg/mL) were measured by enzyme-linked immunosorbent assay method.

<strong class="sub-title"> Results: </strong> There was no significant difference with respect to demographic characteristics between the FMS patients and healthy controls. When clinical parameters were compared, MAF, BDI, BAI, and PSQI scores were significantly higher in FMS patients than controls (p<0.05). Serum <em>nesfatin</em>-<em>1</em> concentration was significantly lower in patients with FMS (p<0.05). When compared to the FMS patients without anxiety, serum <em>nesfatin</em>-<em>1</em> concentration was significantly increased in FMS patients with anxiety (p<0.05). Serum <em>nesfatin</em>-<em>1</em> concentration was positively correlated with BAI scores in patients with FMS (p<0.05).

<strong class="sub-title"> Conclusion: </strong> Low <em>nesfatin</em>-<em>1</em> serum levels may contribute to pathological changes in FMS. In addition, <em>nesfatin</em>-<em>1</em> may also be involved in the mediation of anxiety-related responses in FMS.

<strong class="sub-title"> Keywords: </strong> Anxiety; fibromyalgia syndrome; <em>nesfatin</em>-<em>1</em>.

<strong class="sub-title"> Purpose: </strong> <em>Nesfatin</em>-<em>1</em> is produced in various tissues of the body including the hypothalamus. Neuroprotective properties of the neuropeptide hormone <em>Nesfatin</em>-<em>1</em> were recently described. The aim of the study was to analyze the molecule <em>Nesfatin</em>-<em>1</em> as a possible biomarker in POAG with neuroprotective properties pointing out the retinal-hypothalamic axis as target site in POAG and to obtain a molecular signature of cytokines in POAG as neuroinflammatory processes are a key factor of glaucoma development.

<strong class="sub-title"> Methods: </strong> In this study, n=35 patients with moderate and advanced POAG (mean age 65.0y, IOP <em>1</em>3.9±3.0mmHg) and n=35 healthy controls (mean age 5<em>1</em>.6y, IOP <em>1</em>4.3±2.7mmHg) were included. Clinical parameters including IOP, cup to disc ratio (CDR), glaucoma medication and retinal nerve fiber layer thickness (RNFL) were recorded. Plasma was collected for NUCB2/nesfatin-<em>1</em> measurement using a <em>Nesfatin</em>-<em>1</em> ELISA and for detection of <em>1</em>3 inflammatory cytokines using a multiplex bead-based immunoassay (MagPix). Multiple linear regression analysis was performed to adjust for confounding factors.

<strong class="sub-title"> Results: </strong> Sex-independent or sex-dependent variables showed no significant differences in the <em>Nesfatin</em>-<em>1</em> level (p>0.05). As a trend, an increase in NUCB2/nesfatin-<em>1</em> in male glaucoma patients was found. Increased concentrations of <em>1</em><em>1</em> cytokines (GM-CSF, Interferon-γ, Interleukin-<em>1</em>β, IL-2, 4, 5, 6, 7, <em>1</em>0, <em>1</em>2 and TNF-α) were detected in POAG. The female glaucoma patients demonstrated elevated cytokine concentrations compared to male patients. NUCB2/nesfatin-<em>1</em> showed a significant correlation to IL-2 and IL-<em>1</em>3 levels in POAG. Stepwise multiple regression analysis showed no difference in NUCB2/nesfatin-<em>1</em> level between POAG and healthy controls after adjusting for sex and age (all p>0.05).

<strong class="sub-title"> Conclusion: </strong> As a trend, male POAG patients showed increased plasma NUCB2/nesfatin-<em>1</em> levels. We further found inflammation as contributing factor to the pathogenesis of glaucoma, with a greater inflammatory response in women.

<strong class="sub-title"> Keywords: </strong> NUCB2/nesfatin-<em>1</em>; cytokines; molecular signature; primary open-angle glaucoma.

Nucleobindins (NUCB<em>1</em> and NUCB2) were originally identified as calcium and DNA binding proteins. <em>Nesfatin</em>-<em>1</em> (NEFA/nucleobindin-2-Encoded Satiety and Fat-Influencing proteiN-<em>1</em>) is an 82 amino acid anorexigenic peptide encoded in the N-terminal region of NUCB2. We have shown that <em>nesfatin</em>-<em>1</em> is a cardio suppressor in zebrafish. Both NUCB<em>1</em> and NUCB2 possess a <em>nesfatin</em>-<em>1</em>-like peptide with a very highly conserved bioactive core. It was found that a <em>nesfatin</em>-<em>1</em>-like peptide (NLP) encoded in NUCB<em>1</em> suppresses food intake in fish. In this research, we investigated whether NLP has <em>nesfatin</em>-<em>1</em>-like effects on cardiovascular functions. NUCB<em>1</em>/NLP-like immunoreactivity was found in the atrium and ventricle of the heart and skeletal muscle of zebrafish. Intraperitoneal injection (IP) of either zebrafish NLP or rat NLP suppressed cardiac functions in both zebrafish and goldfish. Irisin and RyR<em>1</em>b mRNA expression was downregulated by NLP in zebrafish cardiac and skeletal muscles. However, cardiac ATP2a2 mRNA expression was elevated by NLP injection. Administration of scrambled NLP did not affect irisin, RyR<em>1</em>b or ATP2a2 mRNA expression in zebrafish. Together, these novel results implicate NLP as a suppressor of cardiovascular physiology in zebrafish and goldfish.

<strong class="sub-title"> Keywords: </strong> Cardiovascular physiology; Goldfish; Heart; <em>Nesfatin</em>-<em>1</em>; <em>Nesfatin</em>-<em>1</em>-Like Peptide; Zebrafish.

<AbstractText>To investigate the diagnostic value of <em>nesfatin</em>-<em>1</em> in cases of intestinal ischemia and ischemia/reperfusion.</AbstractText><AbstractText>An experimental study.</AbstractText><AbstractText>The Experimental Animals Laboratory of Bezmialem University, in June 20<em>1</em>8.</AbstractText><AbstractText>Twenty-one healthy male Sprague Dawley rats were randomly divided into three groups of 7 rats each. In group <em>1</em>: <em>1</em>-hour intestinal ischemia followed by 5-hour reperfusion was performed. In group 2: rats were subjected to 6-hour intestinal ischemia. In group 3: rats underwent laparotomy and closure without performing any further procedure. Changes in leukocyte count, amylase, blood sugar, LDH, SGOT, CRP, and <em>nesfatin</em>-<em>1</em> levels were determined. For histopathological examination, a small intestinal sample was taken and preserved in <em>1</em>0% formaldehyde.</AbstractText><AbstractText><em>Nesfatin</em>-<em>1</em> value in group 2 was significantly higher than that in group <em>1</em> and group 3 (p=0.005, and p <0.00<em>1</em> respectively). <em>Nesfatin</em>-<em>1</em> value in group <em>1</em> was significantly higher than that in group 3. A significant (r = 0.864/p <0.00<em>1</em>) positive correlation was observed between <em>nesfatin</em>-<em>1</em> value and pathology score. The pathology score of group 2 was significantly higher than that of group <em>1</em> and group 3 (p <0.00<em>1</em>).</AbstractText><AbstractText>Serum <em>nesfatin</em>-<em>1</em> can be a biomarker in acute mesenteric ischemia.</AbstractText>

<em>Nesfatin</em>-<em>1</em> is a naturally occurring 82-amino acid protein encoded in the precursor nucleobindin-2 (NUCB2) and has been implicated in multiple physiological functions, including food intake and blood glucose regulation. This study aimed to characterize <em>nesfatin</em>-<em>1</em> in domestic species, especially cats (Felis catus), dogs (Canis lupus familiaris), and pigs (Sus scrofa). Our in silico analysis demonstrated that the NUCB2/<em>nesfatin</em>-<em>1</em> amino acid sequence, especially the bioactive core region of the peptide, is very highly conserved (more than 90% identity) in domestic animals. Expression of mRNAs encoding NUCB2/<em>nesfatin</em>-<em>1</em> was detected in the cat, dog, and pig stomach and pancreas. Immunohistochemistry revealed the presence of <em>nesfatin</em>-<em>1</em> in the gastric mucosa of the stomach of dogs, cats, and pigs, and in the pancreatic islet β-cells of dogs and pigs. No <em>nesfatin</em>-<em>1</em> immunoreactivity was found in the cat pancreas. <em>Nesfatin</em>-<em>1</em> was detected in the serum of dog, cat, pig, bison, cow, horse, sheep, and chicken. Circulating <em>nesfatin</em>-<em>1</em> in male and female dogs remained unchanged at 60 min after glucose administration, suggesting a lack of meal responsiveness in <em>nesfatin</em>-<em>1</em> secretion in this species. The presence of <em>nesfatin</em>-<em>1</em> in the gastric and endocrine pancreatic tissues suggests possible roles for this peptide in the metabolism of domestic animals. Future research should focus on elucidating the species-specific functions and mechanisms of action of <em>nesfatin</em>-<em>1</em> in health and disease of domestic animals.

<em>Nesfatin</em>-<em>1</em> has originally been established as a bioactive peptide interacting with key hypothalamic nuclei and neural circuitries in control of feeding behavior, while its effect on energy expenditure has only recently been investigated. Hence, the aim of this study was to examine whether centrally acting <em>nesfatin</em>-<em>1</em> can induce β₃-adrenergic stimulation, which is a prerequisite for the activation of thermogenic genes and heat release from interscapular brown adipose tissue, key physiological features that underlie increased energy expenditure. This question was addressed in non-fasted mice stereotactically cannulated to receive <em>nesfatin</em>-<em>1</em> intracerebroventricularly together with peripheral injection of the β₃-adrenoceptor antagonist SR 59230 A, to assess whole-body energy metabolism. Using a minimally invasive thermography technique, we now demonstrate that the thermogenic effect of an anorectic <em>nesfatin</em>-<em>1</em> dose critically depends on β₃ adrenergic stimulation, as the co-administration with SR 59230 A completely abolished heat production from interscapular brown adipose tissue and rise in ocular surface temperature, thus preventing body weight loss. Moreover, through indirect calorimetry it could be shown that the anorectic concentration of <em>nesfatin</em>-<em>1</em> augments overall caloric expenditure. Plausibly, central administration of <em>nesfatin</em>-<em>1</em> also enhanced the expression of DIO2 and CIDEA mRNA in brown adipose tissue critically involved in the regulation of thermogenesis.

Aims: The effective treatment of polycystic ovary syndrome (PCOS)-related hormonal disorders necessitates the development of novel treatment strategies. Resveratrol is found in certain food products, and is known to exhibit phytoestrogen properties. The present study was to assess whether resveratrol exhibits beneficial phytoestrogenic effects and associated hormonal modulation in a rat model of PCOS.

<strong class="sub-title"> Materials and methods: </strong> This model was established by administering oral letrozole to female Sprague-Dawley (SD) rats prior to randomizing them into control, model and resveratrol treatment groups (40, 80, or <em>1</em>60 mg/kg). Animals were treated for 30 days, after which time ovarian tissues were collected and evaluated <i>via</i> hematoxylin and eosin staining. In addition, serum levels of estradiol and adiponectin were assessed <i>via</i> ELISA, and ovarian expression of <em>nesfatin</em>-<em>1</em> and aromatase was assessed through RT-PCR and western blotting.

<strong class="sub-title"> Results: </strong> We found that resveratrol administration was associated with increased levels of plasma adiponectin and estradiol levels and restoration of normal ovarian morphology in PCOS model animals. In addition, this treatment was linked to the increased ovarian expression of <em>nesfatin</em>-<em>1</em> and aromatase at the RNA and protein levels.

Conclusions: Together things findings suggest that resveratrol may represent an effective tool for treating PCOS owing to its phytoestrogenic properties.

Keywords: Resveratrol; phytoestrogenic; polycystic ovary syndrome (PCOS).

<AbstractText>Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. <em>Nesfatin</em>-<em>1</em>, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH<em>1</em> and MHS2 genes, c-MET and ARID<em>1</em>A are also related to prognosis in endometrial cancer.</AbstractText><AbstractText>Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF<em>1</em>, MLH<em>1</em>, MSH2,c-MET and ARID<em>1</em>A were examined.</AbstractText><AbstractText>In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of NESF-<em>1</em> in type II EC. In type I EC, NESF-<em>1</em> expression was significantly higher in G<em>1</em> in comparison to G2 and G3 together. A significantly lower expression of MLH<em>1</em> was demonstrated in type I EC.</AbstractText><AbstractText>The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency was detected for a high expression of NESF-<em>1</em> in patients with type II EC, who also exhibited a high expression of MSH2.</AbstractText>

Ghrelin (orexigenic) and <em>nesfatin</em>-<em>1</em> (anorexigenic) are two peptides with opposing actions on food intake regulation and are mainly expressed in the hypothalamus and gut of mammals and fish. Both are involved in the regulation of a wide range of physiological processes in vertebrates, including metabolism, growth, and reproduction. However, the anatomical relationship between these peptides and the nutrient assimilation processes are not well understood. Thus, the aim of this work was to determine the localization of ghrelin, <em>nesfatin</em>-<em>1</em>, and several enzymes involved in the digestive process (lipoprotein lipase, aminopeptidase A, trypsin, and sucrase-isomaltase) in the intestine of pejerrey (Odontesthes bonariensis), a species with commercial importance in South America. We observed co-localization of ghrelin and <em>nesfatin</em>-<em>1</em> in enteroendocrine cells, absorptive cells, and in cells of the lamina propia. Approximately half of the cells displaying ghrelin-like immunoreactivity co-localized the NUCB2/<em>nesfatin</em>-<em>1</em>-like signal. In addition, both peptides showed co-localization with lipoprotein lipase, aminopeptidase A, trypsin, or sucrase-isomaltase. All digestive enzymes except for aminopeptidase A and trypsin, showed high co-localization (68-88%) with both ghrelin-like and NUCB2/<em>nesfatin</em>-<em>1</em>-like signals in absorptive, enteroendocrine, and lamina propria cells. Together, our results provide immunohistochemical evidence supporting a role for both ghrelin and NUCB2/<em>nesfatin</em>-<em>1</em> in the regulation of nutrient assimilation in fish. Anat Rec, 20<em>1</em>8. © 20<em>1</em>8 Wiley Periodicals, Inc.

In the hypothalamic arcuate nucleus (ARC), orexigenic agouti-related peptide (AgRP) neurons regulate feeding behavior and energy homeostasis. The 3-phosphoinositide-dependent protein kinase-<em>1</em> (PDK<em>1</em>) in AgRP neurons serves as a major signaling molecule for leptin and insulin, the hormones regulating feeding behavior, energy homeostasis and circulation. However, it is unclear whether PDK<em>1</em> in AGRP neurons is also involved in regulation of blood pressure. This study explored it by generating and analyzing AgRP neuron-specific PDK<em>1</em> knockout (Agrp-Pdk<em>1</em>flox/flox) mice and effect of high salt diet on blood pressure in KO and WT mice was analyzed. Under high salt diet feeding, systolic blood pressure (SBP) of Agrp-Pdk<em>1</em>flox/flox mice was significantly elevated compared to Agrp-Cre mice. When the high salt diet was switched to control low salt diet, SBP of Agrp-Pdk<em>1</em>flox/flox mice returned to the basal level observed in Agrp-Cre mice within <em>1</em> week. In Agrp-Pdk<em>1</em>flox/flox mice, urinary noradrenalin excretion and NUCB2 mRNA expression in hypothalamic paraventricular nucleus (PVN) were markedly upregulated. Moreover, silencing of NUCB2 in the PVN counteracted the rises in urinary noradrenalin excretions and SBP. These results demonstrate a novel role of PDK<em>1</em> in AgRP neurons to counteract the high salt diet-induced hypertension by preventing hyperactivation of PVN <em>nesfatin</em>-<em>1</em> neurons.

<strong class="sub-title"> Introduction: </strong> Ischaemic stroke (IS) is a disease being the common cause of death and one of the most common causes of disability in adults. There is a continuous need for conducting stroke pathogenesis studies. A certain role here can be attributed to adipose-derived hormones. The aim of this paper is to assess the blood concentration for selected adipocytokines: omentin-<em>1</em>, irisin, protein-<em>1</em> related with C<em>1</em>q / TNF (CTRP<em>1</em>), vaspin and <em>nesfatin</em>-<em>1</em> in IS patients and an attempt to define their role as risk factors for ischaemic stroke.

<strong class="sub-title"> Materials and methods: </strong> The study included 46 patients with ischaemic stroke (27 females, <em>1</em>9 males, average 67.6 years of age).The control group consisted of 32 patients (<em>1</em>6 females, <em>1</em>6 males, average 64.<em>1</em> years of age) who had never suffered cerebrovascular diseases.

<strong class="sub-title"> Results: </strong> The concentration of omentin-<em>1</em> and CTRP<em>1</em> in the group of stroke patients was higher than in the control group, whereas the concentrations of <em>nesfatin</em>-<em>1</em> and irisin - significantly lower than in the control group. The vaspin level was similar in both groups of patients. Statistical analysis using logistic regression allows us to find that CTRP<em>1</em> can be a significant stroke risk factor. A statistically significant positive correlation was found between the concentration of CTRP<em>1</em> and the NIHSS. However, no correlation between the concentration of other adipocytokines under investigation and the severity of ischaemic stroke was found.

<strong class="sub-title"> Conclusions: </strong> From among the adipocytokines under investigation higher concentrations of omentin-<em>1</em> and CTRP<em>1</em> and lower blood concentrations of <em>nesfatin</em>-<em>1</em>, irisin significantly increase the odds of getting to the group of ischaemic patients. It seems that CTRP<em>1</em> can be an independent predictive factor of IS.

<strong class="sub-title"> Keywords: </strong> CTRP<em>1</em>; adipocytokines; irisin; ischaemic stroke; <em>nesfatin</em>-<em>1</em>; omentin-<em>1</em>; vaspin.

<AbstractText>We hypothesized that <em>nesfatin</em>-<em>1</em>, an anti-inflammatory peptide, could be used as a non-invasive diagnostic tool in the identification of celiac disease (CD) and irritable bowel syndrome presenting predominantly with diarrhea (IBS-D).</AbstractText><AbstractText>Thirty-five patients with IBS-D who met the Rome III criteria, 28 patients with celiac disease who met the diagnostic criteria of the Marsh-Oberhuber classification, and 30 age- and gender-matched healthy controls were included in this cross-sectional study. All subjects responded to the IBS Severity Scoring System (IBS-SSS) questionnaire that was used to determine pain severity, pain frequency, bloating, dissatisfaction with bowel habits, and life interference.</AbstractText><AbstractText><em>Nesfatin</em>-<em>1</em> levels were significantly higher in the CD group compared to the IBS-D group and healthy controls. <em>Nesfatin</em>-<em>1</em> was also higher in the IBS-D group compared to controls. <em>Nesfatin</em>-<em>1</em> levels were correlated with IBS-SSS (r = 0.884, p < 0.00<em>1</em>), severity of abdominal pain and discomfort (r = 0.644, p < 0.00<em>1</em>), and C-reactive protein concentrations (r = 0.303, p = 0.004). ROC curve analysis demonstrated that a cutoff value of > 98.<em>1</em> pg/mL for <em>nesfatin</em>-<em>1</em> could discriminate subjects with CD from those with IBS-D and also healthy controls with a sensitivity of 82% and a specificity of 80%.</AbstractText><AbstractText>The results of this study show that subjects with CD have higher <em>nesfatin</em>-<em>1</em> levels compared to those with IBS-D or to the healthy controls. Moreover, <em>nesfatin</em>-<em>1</em> can discriminate subjects with CD from those with IBS-D and also healthy controls, with high sensitivity and specificity. Further studies with histopathological evaluation are required to clearly address the role of <em>nesfatin</em>-<em>1</em> in the diagnosis of CD.</AbstractText>

Physical exercise is known to influence hormonal mediators of appetite, but the effect of short-term maximal intensity exercise on plasma levels of appetite hormones and cytokines has been little studied. We investigated the effect of a 30 s Wingate Test, followed by a postprandial period, on appetite sensations, food intake, and appetite hormones. Twenty-six physically active young males rated their subjective feelings of hunger, prospective food consumption, and fatigue on visual analogue scales at baseline, after exercise was completed, and during the postprandial period. Blood samples were obtained for the measurement of <em>nesfatin</em>-<em>1</em>, ghrelin, leptin, insulin, pancreatic polypeptide (PP), human growth factor (hGH) and cytokine interleukin-6 (IL-6), irisin and plasma lactate concentrations, at 30 min before exercise, immediately (2<em>1</em>0 s) after exercise, and 30 min following a meal and at corresponding times in control sedentary males without ad libitum meal intake, respectively. Appetite perceptions and food intake were decreased in response to exercise. Plasma levels of irisin, IL-6, lactate, <em>nesfatin</em>-<em>1</em> and ghrelin was increased after exercise and then it was returned to postprandial/control period in both groups. A significant rise in plasma insulin, hGH and PP levels after exercise was observed while meal intake potentiated this response. In conclusion, an acute short-term fatiguing exercise can transiently suppress hunger sensations and food intake in humans. We postulate that this physiological response involves exercise-induced alterations in plasma hormones and the release of myokines such as irisin and IL-6, and supports the notion of existence of the skeletal muscle-brain-gut axis. Nevertheless, the detailed relationship between acute exercise releasing myokines, appetite sensations and impairment of this axis leading to several diseases should be further examined.

<strong class="sub-title"> Keywords: </strong> appetite hormones; ghrelin; interleukin-6; irisin; <em>nesfatin</em>-<em>1</em>; pancreatic polypeptide; sprint-exercise.

The aim of the research was to assess the effect of <em>nesfatin</em>-<em>1</em> on the structure, flexibility parameters, and expression of adropin, <em>nesfatin</em>-<em>1</em>, and angiotensin II receptor type <em>1</em> (AT<em>1</em>R) in the abdominal aorta in ovariectomized rats. Fragments of aortas were collected after euthanasia of female sham-operated (CONT) and ovariectomized Wistar rats (EXP), which were administered intraperitoneal injection of physiological saline (CONT, n = 7; EXP-O, n = 7) or <em>nesfatin</em>-<em>1</em> (EXP-N, n = 7) in an amount of 2 μg/kg b.w. once a day for 8 weeks. The samples of aortas were collected for measurement of elasticity as well as histomorphometric, immunohistochemical, FTIR, and Raman spectroscopy analysis. The ovariectomy caused a significant increase in the thickness of the total wall and its particular layers in the aorta, in comparison to the CONT and EXP-N groups. However, the ovariectomy led to a decrease in the amount of elastin, collagen (mature, immature collagen, collagen maturity ratio <em>1</em>660 - <em>1</em>690 cm^-<em>1</em>), and amides, with a simultaneous increase in lipids, especially in the tunica intima-media of the abdominal aorta compared to the other groups. The use of <em>nesfatin</em>-<em>1</em> significantly increased the amount of collagen, elastin and amides with a simultaneous decrease in the amount of lipids and the expression of AT<em>1</em>R, adropin and <em>nesfatin</em>-<em>1</em> in the abdominal aorta of ovariectomized rats. In conclusion, our study showed that the ovariectomy surgery induced changes in the abdominal aorta wall characteristic for aging females. Application of <em>nesfatin</em>-<em>1</em> may prevent the negative consequences in the vessel wall structure in females in conditions of estrogen deficiency and prevent atherosclerotic changes in the cardiovascular system.

<AbstractText><em>Nesfatin</em>-<em>1</em> is a novel anorectic neuropeptide with potent metabolic regulatory effects. <em>Nesfatin</em>-<em>1</em> regulates blood pressure, heart rate, cardiomyocyte metabolism, and permeability. We aimed to evaluate the relationship between carotid artery stenosis (CAS) and <em>nesfatin</em>-<em>1</em>.</AbstractText><AbstractText>Three groups were established as patients with no atherosclerotic plaques (n = 60), CAS <60% (n = 60), and CAS ≥60% (n = 60). Then, patients with CAS were divided into 2 subgroups as patients with calcific (n = 67) and non-calcific (n = 53) carotid artery stenosis according to plaque morphological features. <em>Nesfatin</em>-<em>1</em> levels and baseline data were compared between groups.</AbstractText><AbstractText>Serum <em>nesfatin</em>-<em>1</em> levels were higher in the control group than CAS <60% group (p < .00<em>1</em>). Serum <em>nesfatin</em>-<em>1</em> levels were also higher in CAS <60% group than CAS ≥60% group (p < .00<em>1</em>). Multivariable logistic regression analyses demonstrated that serum <em>nesfatin</em>-<em>1</em> levels were independently associated with CAS. In addition, <em>nesfatin</em>-<em>1</em> levels were higher in calcific plaques.</AbstractText><AbstractText><em>Nesfatin</em>-<em>1</em> levels are inversely associated with severtiy of CAS and plaque morphology.</AbstractText>

<em>Nesfatin</em>-<em>1</em>, which is an anorexiogenic peptide, plays a crucial role as a neurotransmitter and/or neuromodulator in the central nervous system for cardiovascular control and energy balance etc. It is expressed abundantly in multiple brain nuclei including central respiratory control areas such as nucleus tractus solitarius, nucleus ambiguous, dorsal vagal complex, dorsal motor nucleus of the vagus nerve, and hypothalamus. To date, no previous studies have been found to report <em>nesfatin</em>-<em>1</em>-evoked respiratory effects. Therefore, the present study was designed to investigate the possible impacts of centrally and/or peripherally injected <em>nesfatin</em>-<em>1</em> on respiratory parameters in either <em>1</em>2h-fasted or fed-ad libitum rats. Intracerebroventricular (ICV) administration of <em>nesfatin</em>-<em>1</em> provoked significant hyperventilation by increasing tidal volume (TV), respiratory rate (RR) and respiratory minute ventilation (RMV) in both the <em>1</em>2h-fasted and the fed-ad libitum Spraque Dawley rats in dose- and time- dependent manner. Moreover, the hyperventilatory effects of centrally injected <em>nesfatin</em>-<em>1</em> were more potent in the fed-ad libitum rats. Intravenous injection of <em>nesfatin</em>-<em>1</em> induced a significant rise in RR and RMV, but not in TV, in the fed-ad libitum rats. In conclusion, these findings plainly report that both centrally and/or peripherally injected <em>nesfatin</em>-<em>1</em> induces significant hyperventilatory effects in the <em>1</em>2h-fasted and the fed-ad libitum rats. These hyperventilatory effects of <em>nesfatin</em>-<em>1</em> might show a discrepancy according to the food intake of the rats and the delivery method of the peptide.

<em>Nesfatin</em>-<em>1</em>, identified as an anorexigenic peptide, regulates the energy metabolism by suppressing food intake. The majority of <em>nesfatin</em>-<em>1</em>-synthesizing neurons are concentrated in various hypothalamic nuclei, especially in the supraoptic (SON), arcuate (ARC) and paraventricular nuclei (PVN). We tested the hypothesis that the glutamatergic system regulates <em>nesfatin</em>-<em>1</em> neurons through glutamate receptors. Therefore, the first aim of the proposed studies was to examine effects of different glutamate agonists in the activation of <em>nesfatin</em>-<em>1</em> neurons using c-Fos double immunohistochemical labeling. Experimental groups were formed containing male and female rats which received intraperitoneal injections of glutamate agonists kainic acid, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) while the control rats received vehicle. The significant increase in the number of c-Fos-expressing <em>nesfatin</em>-<em>1</em> neurons after agonist injections were observed both in female and male subjects and some of these effects were found to be sexually dimorphic. In addition, treatment with specific glutamate antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) or dizocilpine (MK-80<em>1</em>) before each of the three agonist injections caused a statistically significant reduction in the number of activated <em>nesfatin</em>-<em>1</em> neurons in the hypothalamic nuclei including supraoptic, paraventricular and arcuate nuclei. The second aim of the study was to determine the expression of glutamate receptor subunit proteins in the <em>nesfatin</em>-<em>1</em> neurons by using a double immunofluorescence technique. The results showed that the glutamate receptor subunits, which may form homomeric or heteromeric functional receptor channels, were expressed in the <em>nesfatin</em>-<em>1</em> neurons. In conclusion, the results of this study suggest that <em>nesfatin</em>-<em>1</em> neurons respond to glutamatergic signals in the form of neuronal activation and that the glutamate receptors that are synthesized by <em>nesfatin</em>-<em>1</em> neurons may participate in the glutamatergic regulation of these neurons.

<strong class="sub-title"> Keywords: </strong> c-Fos; glutamate; hypothalamus; <em>nesfatin</em>-<em>1</em>; rat.

<AbstractText>To investigate the use of <em>nesfatin</em>-<em>1</em> and caspase-cleaved cytokeratin-<em>1</em>8 serum levels as biomarkers in Alzheimer's disease.</AbstractText><AbstractText>The study group consisted of 39 patients with Alzheimer's disease (AD) and 39 controls. Demographic characteristics including gender, age, body mass index, mini-mental status examination (MMSE) and duration of disease were recorded. The ELISA method was used to measure serum <em>nesfatin</em>-<em>1</em> and CCCK-<em>1</em>8 levels in serum samples.</AbstractText><AbstractText>Serum <em>nesfatin</em>-<em>1</em> levels were statistically significantly higher in the AD patient group than in controls. There was no significant difference between the groups with regards to serum CCCK-<em>1</em>8 levels. Pearson analysis showed no significant correlation between serum <em>nesfatin</em>-<em>1</em>, serum CCCK-<em>1</em>8 levels, mini-mental status examination and disease duration.</AbstractText><AbstractText>This study proved that serum <em>nesfatin</em>-<em>1</em> levels can be used as a biomarker in Alzheimer's disease by showing a statistically significant high level of serum <em>nesfatin</em>-<em>1</em> in patients with Alzheimer's disease. This is the first study to suggest that <em>nesfatin</em>-<em>1</em> can be used as a biomarker in Alzheimer's disease. In addition, our study showed that CCCK-<em>1</em>8 can be used as a prognostic biomarker for Alzheimer's disease. Further comprehensive studies should be done to clarify the use of serum <em>nesfatin</em>-<em>1</em> and CCCK-<em>1</em>8 levels as biomarkers for Alzheimer disease (Tab. 3, Fig. 2, Ref. 25).</AbstractText>

<p><div><b>Background</b></div>Failure to respond adequately to standard protocols and to recruit adequate follicles is called 'poor ovarian response'. The relationships between metabolic alterations and NUCB2/<em>Nesfatin</em>-<em>1</em> levels were explored in patients with polycystic ovary syndrome (PCOS) undergoing <i>in vitro</i> fertilization/intracytoplasmic sperm injection.</p><AbstractText>This case-control study involved 20 infertile women with PCOS and 20 control women diagnosed as poor ovarian responders stimulated with a GnRH antagonist. Blood samples were taken during ovum pick-up and follicular fluids (FF) were obtained from a dominant follicle from the subjects. Samples were analyzed by using ELISA. Statistical analysis was performed with SPSS version 20. Data are expressed as means ± standard deviation (SD).</AbstractText><AbstractText>Blood NUCB2/<em>Nesfatin</em>-<em>1</em> levels in PCOS were significantly lower (p= 0.0<em>1</em><em>1</em>) while the NUCB2/<em>Nesfatin</em>-<em>1</em> levels of FF in poor ovarian response (POR) were higher, but not statistically significant. Insulin, total testosterone, fasting glucose, homeostasis model assessment, and insulin resistance index in women with POR decreased when compared with PCOS. Blood NUCB2/<em>Nesfatin</em>-<em>1</em> levels were significantly higher than FF NUCB2/<em>Nesfatin</em>-<em>1</em> levels in both groups (p<0.00<em>1</em>). Moreover, a positive correlation was detected between blood NUCB2/<em>Nesfatin</em>-<em>1</em> and testosterone (p=0.602, r=0.304), HOMA-IR (p=0.252, r=0.384), BMI (p=0.880, r= 0.44) in PCOS, but it was not significant.</AbstractText><AbstractText>NUCB2/<em>Nesfatin</em>-<em>1</em> levels might be important in follicular growth in PCOS subjects undergoing IVF/ICSI with an antagonist protocol and NUCB2/<em>Nesfatin</em>-<em>1</em> level could reliably help to predict poor ovarian response.</AbstractText>

We evaluated the relationship between <em>nesfatin</em>-<em>1</em> and acute myocardial infarction (AMI) and Mediterranean diet scores. 67 patients with AMI and 33 patients with normal coronary arteries (control group) were included in the study. The patients with AMI were divided into 2 groups based on low (<32) (n = 33) and high values of the synergy between percutaneous coronary intervention with Taxus and cardiac surgery (SYNTAX) scores (≥34) (n = 35). Mediterranean diet score, serum <em>nesfatin</em>-<em>1</em> concentrations and all other data were compared between the groups. Serum <em>nesfatin</em>-<em>1</em> concentrations were significantly lower in 67 AMI patients (both the high and low SYNTAX groups) than in the control group (p < 0.00<em>1</em>). Moreover, serum <em>nesfatin</em>-<em>1</em> concentrations were lower in the high SYNTAX group than those in the low SYNTAX group (p < 0.00<em>1</em>). There were positive correlations between the serum <em>nesfatin</em>-<em>1</em> concentrations and Mediterranean diet scores in both the AMI patients and the control subjects, and there was a negative correlation between the serum <em>nesfatin</em>-<em>1</em> concentrations and SYNTAX scores in the AMI patients. This study has shown that serum <em>nesfatin</em>-<em>1</em> concentrations are closely related to the severity of AMI and Mediterranean diet scores.